Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | RXFP1 | Q9HBX9 | 5/20 | 0.62 |
| ▸ | P2RX1 | P51575 | 4/20 | 0.60 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.55 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.54 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.54 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.54 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1598335 | 0.87 | MAPT (0.69) | MAPTRXFP1P2RX1KCNK3LMNA | |
| SCHEMBL826721 | 0.85 | MAPT (0.83) | MAPTRXFP1P2RX1KCNK3LMNA | |
| SCHEMBL4174614 | 0.83 | NR1H4 (0.65) | MEN1KMT2ARAB9ANPC1 | |
| SCHEMBL2859341 | 0.82 | MEN1 (0.78) | MAPTRXFP1P2RX1KCNK3LMNA | |
| SCHEMBL4286068 | 0.82 | MAPT (0.94) | MAPTRXFP1P2RX1KCNK3LMNA | |
| SCHEMBL3028309 | 0.81 | MAPT (0.76) | MAPTRXFP1P2RX1KCNK3LMNA | |
| SCHEMBL7816780 | 0.81 | MEN1 (0.76) | MAPTRXFP1P2RX1KCNK3LMNA | |
| SCHEMBL12581365 | 0.80 | RXFP1 (0.63) | MAPTRXFP1P2RX1KCNK3LMNA | |
| SCHEMBL13639753 | 0.79 | RXFP1 (0.62) | MAPTRXFP1P2RX1KCNK3MEN1 | |
| SCHEMBL28151432 | 0.79 | IDH2 (0.69) | MAPTRXFP1KCNK3LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1948146-B1 | NOVEL MULTI-CYCLIC COMPOUNDS AND THEIR USE | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2012-11-07 | — | — | EP | disclosed |
| US-20090030015-A1 | NOVEL MULTI-CYCLIC COMPOUNDS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2009-01-29 | — | — | US | disclosed |
| US-20090030015-A1 | NOVEL MULTI-CYCLIC COMPOUNDS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2009-01-29 | — | — | US | disclosed |
| WO-2007039111-A2 | NOVEL MULTI-CYCLIC COMPOUNDS AND THEIR USE | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030015-A1 | NOVEL MULTI-CYCLIC COMPOUNDS | SELP, SELE, SELL | MAPT 4021/4885RXFP1 2767/4885P2RX1 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.